New pill shows promise for Long-Term control of binge eating

NCT ID NCT06878976

ENROLLING_BY_INVITATION Disease control Sponsor: Axsome Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This Phase 3 study tests the long-term safety and effectiveness of the drug solriamfetol in 300 adults with binge eating disorder. Participants take a daily pill (75, 150, or 300 mg) and are monitored for side effects and changes in binge eating. The study is open-label, meaning everyone knows they are getting the drug, and only includes people who completed a prior related study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Solriamfetol (75 mg, 150 mg, or 300 mg taken once daily)
What this could lead to: If successful, this could provide a long-term medication option to help control binge eating episodes in adults with binge eating disorder.
What could go wrong: This is an open-label study (no placebo), so results may be biased. It only includes people who completed a prior study, so findings may not apply to all patients. Long-term side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

binge eating disorder Binge-Eating Disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BINGE-EATING DISORDER

Contacts and locations

Locations

Clinical Research Site

Encino, California, 91316, United States
Clinical Research Site

Long Beach, California, 90806, United States
Clinical Research Site

Santa Ana, California, 92705, United States
Clinical Research Site

Walnut Creek, California, 94596, United States
Clinical Research Site

West Covina, California, 91790, United States
Clinical Research Site

Cromwell, Connecticut, 06416, United States
Clinical Research Site

Fort Myers, Florida, 33912, United States
Clinical Research Site

Jacksonville, Florida, 32256, United States
Clinical Research Site

Lauderhill, Florida, 33319, United States
Clinical Research Site

Miami, Florida, 33145, United States
Clinical Research Site

Miami, Florida, 33176, United States
Clinical Research Site

Miami Lakes, Florida, 33016, United States
Clinical Research Site

Orlando, Florida, 32801, United States
Clinical Research Site

Marietta, Georgia, 30060, United States
Clinical Research Site

Overland Park, Kansas, 66210, United States
Clinical Research Site

Boston, Massachusetts, 02131, United States
Clinical Research Site

Saint Charles, Missouri, 63304, United States
Clinical Research Site

Cherry Hill, New Jersey, 08002, United States
Clinical Research Site

Mount Kisco, New York, 10549, United States
Clinical Research Site

New York, New York, 10128, United States
Clinical Research Site

Raleigh, North Carolina, 27607, United States
Clinical Research Site

Cincinnati, Ohio, 45215, United States
Clinical Research Site

Mason, Ohio, 45040, United States
Clinical Research Site

Middleburg Heights, Ohio, 44130, United States
Clinical Research Site

North Canton, Ohio, 44720, United States
Clinical Research Site

Portland, Oregon, 97210, United States
Clinical Research Site

Allentown, Pennsylvania, 18103, United States
Clinical Research Site

North Charleston, South Carolina, 29405, United States
Clinical Research Site

Memphis, Tennessee, 38119, United States
Clinical Research Site

Austin, Texas, 78731, United States
Clinical Research Site

Austin, Texas, 78737, United States
Clinical Research Site

Dallas, Texas, 75251, United States
Clinical Research Site

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.